Annexin Pharmaceuticals AB (publ) has entered into a license agreement with Stanford University, CA, USA granting Annexin Pharmaceuticals exclusive license to patent rights related to use of Annexin A5 in treatment of cancer. The license involves a novel therapeutic concept for treating cancer by administration of the Annexin A5 protein, functionally identical to Annexin Pharmaceuticals' drug candidate ANXV. Studies have shown that Annexin A5 acts as a potent immunomodulating anti-cancer agent acting via blocking phosphatidylserine (PS) on cancer cells (US patent No 11,253,568).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.297 SEK | +2.41% | +10.00% | +14.23% |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+14.23% | 9.39M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- ANNX Stock
- News Annexin Pharmaceuticals AB
- Annexin Signs Exclusive Licensing Deal in Cancer